ASTRO develops brain metastases guideline

February 8, 2012, American Society for Radiation Oncology

The American Society for Radiation Oncology (ASTRO) has developed a guideline on the radiotherapeutic and surgical management for newly diagnosed brain metastases. It has been published in Practical Radiation Oncology (PRO), ASTRO's official clinical practice journal.

"This guideline was developed by an international multidisciplinary task force charged with systematically reviewing and synthesizing level one and other high-quality data into a distilled work product," Eric L. Chang, MD, a radiation oncologist at the University of Southern California Keck School of Medicine, said. "It should help clinicians make solid evidence-based decisions, while still allowing best to fill in not readily addressed by the guideline."

Brain metastases occur in an estimated 20 to 40 percent of cancer patients at some point during the course of their illness, and several modalities exist for treatment, including whole brain radiotherapy (WBRT), resection and stereotactic radiosurgery. These treatments have advanced dramatically over the past 30 years, when options were limited to steroids, whole brain radiotherapy and, in rare instances, surgery.

This guideline recommends that the most important endpoint (i.e., survival, quality of life, brain control or neurocognitive function) in a patient's treatment should be the deciding factor in choosing a treatment modality.

Guidance is provided on using WBRT, radiosurgery and/or surgery for three categories of patients based on tumor factors and prognosis:

  1. Single brain metastases and good prognosis (expected survival three months or more).
  2. Multiple brain metastases and good prognosis (expected survival three months or more).
  3. Patient with (expected survival less than three months).

The guideline also answers several questions on the radiotherapeutic and surgical management of newly diagnosed brain metastases.

" represent a significant health care problem, and with the wide array of treatment options it is important to provide guidance on using these modalities" May N. Tsao, MD, a at the Odette Cancer Centre in Toronto, Ontario, Canada, said. "However, the ultimate decision in a patient's care should always be made by a physician taking into consideration the medical history of each individual patient."

Explore further: ASTRO publishes evidence-based guideline for thoracic radiotherapy

More information: For a copy of the guideline, visit www.astro.org/Clinical-Practic … rain-metastases.aspx

Related Stories

ASTRO publishes evidence-based guideline for thoracic radiotherapy

April 27, 2011
The American Society for Radiation Oncology (ASTRO) has developed a guideline for the use of external beam radiation therapy, endobronchial brachytherapy and concurrent chemotherapy to palliate thoracic symptoms caused by ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.